



## Somaxon Pharmaceuticals, Inc. To Present At The 24<sup>th</sup> Annual JPMorgan Healthcare Conference

SAN DIEGO, CA – Jan 5, 2006 – Somaxon Pharmaceuticals, Inc., (NASDAQ: SOMX) today announced that Kenneth Cohen, President and Chief Executive Officer, will present a company update at the 24<sup>th</sup> Annual JPMorgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2006 at 10:00 a.m. PST.

Interested parties will be able to listen to a live webcast of the presentation by visiting [www.somaxon.com](http://www.somaxon.com) and connecting via a link to the JPMorgan website at <http://equityconferences.jpmorgan.com>. Visitors should select the JPMorgan Healthcare Conference link and register. A replay of the webcast will be archived until Thursday, January 26, 2006.

### About Somaxon Pharmaceuticals

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon's lead product, SILENOR™, is in Phase III clinical trials for the treatment of insomnia.

### Contact:

Investors please contact Meg McGilley, CFO (858.509.3670), or Rob Whetstone, Pondel/Wilkinson, Inc. (310.279.5980).

Media please contact Jeff Raser, Sr. VP. (858.509.3670).

Web site: [www.somaxon.com](http://www.somaxon.com).